miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway

miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway

Background/Aims: KRas is usually mutated in non-small cell lung cancer (NSCLC). The mutated KRas gene is a negative prognostic indicator that promotes tumor proliferation, metastasis, and drug resistance in NSCLC, and thus has become a target for cancer therapy. This study is focused on the effects...

Full description

Bibliographic Details
Main Authors: Wei Sun, Wei Ping, Yitao Tian, Wenbin Zou, Jiawei Liu, Yukun Zu
Format: Article
Language:English
Published: Cell Physiol Biochem Press GmbH & Co KG 2018-12-01
Series:Cellular Physiology and Biochemistry
Subjects:
miR-202
KRas
MAPK
Cisplatin
NSCLC
Online Access:https://www.karger.com/Article/FullText/495835

Internet

https://www.karger.com/Article/FullText/495835

Similar Items